Protocol for the pilot randomized trial of the CArdiovascular Risk assEssment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention

Joan Weiner, Geyanne Lui, Mackenzie Brown, Yuliana Domínguez Páez, Shelley Fritz, Tien Sydnor-Campbell, Aberdeen Allen Jr, Assem Jabri, Shilpa Venkatachalam, Kelly Gavigan, William Benjamin Nowell, Jeffrey R Curtis, Liana Fraenkel, Monika Safford, Iris Navarro-Millán, Joan Weiner, Geyanne Lui, Mackenzie Brown, Yuliana Domínguez Páez, Shelley Fritz, Tien Sydnor-Campbell, Aberdeen Allen Jr, Assem Jabri, Shilpa Venkatachalam, Kelly Gavigan, William Benjamin Nowell, Jeffrey R Curtis, Liana Fraenkel, Monika Safford, Iris Navarro-Millán

Abstract

Background: Cardiovascular disease (CVD) is the most common cause of death among people with rheumatoid arthritis (RA), with an estimated increased risk of 50-60% compared to the general population. Lipid-lowering strategies have been shown to lower CVD risk significantly in people with RA and hyperlipidemia. Thus, CVD risk assessment has an important role to play in reducing CVD among people with RA. Yet currently only 37 to 45% of this population are receiving primary lipids screening. This paper describes the CArdiovascular Risk assEssment for RA (CARE RA) intervention, which is designed to address this issue. CARE RA is a peer coach intervention, that is, an intervention in which a person with RA coaches another person with RA, which is designed to educate people with RA about the relation between RA and CVD risk and to help them obtain evidence-based CVD risk assessment and treatment.

Methods: This is an open-label pilot study that will test if the participants assigned to complete the CARE RA curriculum with a peer coach will receive a cardiovascular risk assessment more frequently compared to those that complete the CARE RA curriculum by themselves. The CARE RA intervention is guided by Social Cognitive Theory. Participants in the peer coach intervention arm will receive the assistance of a peer coach who will call the participants once a week for 5 weeks to go over the CARE RA curriculum and train them on how to obtain CVD risk assessment. The control arm will complete the CARE RA curriculum without any assistance. Participants will be randomized 1:1 either to the control arm or to the peer coach intervention arm. The primary outcome is a participant's having a CVD risk assessment or initiating a statin, if indicated. Secondary outcomes include patient activation and RA medication adherence. The RE-AIM implementation framework guides the implementation and evaluation of the intervention.

Discussion: This pilot study will test the feasibility of the peer coach intervention in anticipation of a larger trial. CARE RA pioneers the use of peer coaches to facilitate the implementation of evidence-based treatment guidelines among people with RA.

Trial registration: ClinicalTrials.gov NCT04488497 . Registered on July 28, 2020.

Keywords: Cardiovascular disease; Implementation science; Peer coaches; Rheumatoid arthritis.

Conflict of interest statement

INM received speaker fees from Sobi. The other authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
CONSORT diagram
Fig. 2
Fig. 2
CARE RA components

References

    1. Kvalvik AG, Jones MA, Symmons DP. Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992. Scand J Rheumatol. 2000;29(1):29–37. doi: 10.1080/030097400750001770.
    1. John H, Kitas G, Toms T, Goodson N. Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):71–82. doi: 10.1016/j.berh.2008.11.007.
    1. England BR, Sayles H, Michaud K, et al. Cause-specific mortality in male US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016;68(1):36–45. doi: 10.1002/acr.22642.
    1. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697. doi: 10.1002/art.24092.
    1. Goodson NJ, Wiles NJ, Lunt M, Barrett EM, Silman AJ, Symmons DP. Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum. 2002;46(8):2010–2019. doi: 10.1002/art.10419.
    1. Meune C, Touze E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 2009;48(10):1309–1313. doi: 10.1093/rheumatology/kep252.
    1. An JJ, Alemao E, Reynolds K, Kawabata H, Solomon DH, Liao KP, Niu F, Cheetham TC. Cardiovascular Outcomes Associated with Lowering Low-density Lipoprotein Cholesterol in Rheumatoid Arthritis and Matched Nonrheumatoid Arthritis. J Rheumatol. 2016;43(11):1989–96.
    1. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2018;139 (25):1082–143.
    1. Bartels CM, Kind AJ, Everett C, Mell M, McBride P, Smith M. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. Arthritis Rheum. 2011;63(5):1221–1230. doi: 10.1002/art.30239.
    1. Navarro-Millan I, Yang S, Chen L, et al. Screening of hyperlipidemia among patients with rheumatoid arthritis in the United States. Arthritis Care Res (Hoboken) 2019;71(12):1593–1599. doi: 10.1002/acr.23810.
    1. Aspry KE, Furman R, Karalis DG, et al. Effect of health information technology interventions on lipid management in clinical practice: a systematic review of randomized controlled trials. J Clin Lipidol. 2013;7(6):546–560. doi: 10.1016/j.jacl.2013.10.004.
    1. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960–977. doi: 10.1136/annrheumdis-2016-210715.
    1. Danninger K, Hoppe UC, Pieringer H.. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis? Int J Rheum Dis. 2014;17:606–11.
    1. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers. J Manag Care Pharm. 2005;11(9):763–771. doi: 10.18553/jmcp.2005.11.9.763.
    1. Koenigsfeld CF, Horning KK, Logemann CD, Schmidt GA. Medication therapy management in the primary care setting: a pharmacist-based pay-for-performance project. J Pharm Pract. 2012;25(1):89–95. doi: 10.1177/0897190011416671.
    1. Woodward A, Wallymahmed M, Wilding J, Gill G. Successful cardiovascular risk reduction in Type 2 diabetes by nurse-led care using an open clinical algorithm. Diabetic Med. 2006;23(7):780–787. doi: 10.1111/j.1464-5491.2006.01889.x.
    1. Charrois TL, Zolezzi M, Koshman SL, et al. A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy. 2012;32(3):222–233. doi: 10.1002/j.1875-9114.2012.01022.x.
    1. Machado M, Nassor N, Bajcar JM, Guzzo GC, Einarson TR. Sensitivity of patient outcomes to pharmacist interventions. Part III: systematic review and meta-analysis in hyperlipidemia management. Ann Pharmacother. 2008;42(9):1195–1207. doi: 10.1345/aph.1K618.
    1. Cording MA, Engelbrecht-Zadvorny EB, Pettit BJ, Eastham JH, Sandoval R. Development of a pharmacist-managed lipid clinic. Ann Pharmacother. 2002;36(5):892–904. doi: 10.1345/aph.1A158.
    1. Bell C, Rowe IF. The recognition and assessment of cardiovascular risk in people with rheumatoid arthritis in primary care: a questionnaire-based study of general practitioners. Musculoskeletal Care. 2011;9(2):69–74. doi: 10.1002/msc.196.
    1. Ab E, Denig P, van Vliet T, Dekker JH. Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study. BMC Fam Pract. 2009;10:24. doi: 10.1186/1471-2296-10-24.
    1. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients’ requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995–2002. doi: 10.1001/jama.293.16.1995.
    1. Stone EG, Morton SC, Hulscher ME, et al. Interventions that increase use of adult immunization and cancer screening services: a meta-analysis. Ann Intern Med. 2002;136(9):641–651. doi: 10.7326/0003-4819-136-9-200205070-00006.
    1. Leveille SG, Huang A, Tsai SB, Allen M, Weingart SN, Iezzoni LI. Health coaching via an internet portal for primary care patients with chronic conditions: a randomized controlled trial. Med Care. 2009;47(1):41–47. doi: 10.1097/MLR.0b013e3181844dd0.
    1. Szilagyi PG, Bordley C, Vann JC, et al. Effect of patient reminder/recall interventions on immunization rates: A review. JAMA. 2000;284(14):1820–1827. doi: 10.1001/jama.284.14.1820.
    1. Szilagyi PG, Schaffer S, Shone L, et al. Reducing geographic, racial, and ethnic disparities in childhood immunization rates by using reminder/recall interventions in urban primary care practices. Pediatrics. 2002;110(5):e58. doi: 10.1542/peds.110.5.e58.
    1. Turner BJ, Day SC, Borenstein B. A controlled trial to improve delivery of preventive care: physician or patient reminders? J Gen Intern Med. 1989;4(5):403–409. doi: 10.1007/BF02599691.
    1. Bartels CM, Roberts TJ, Hansen KE, et al. Rheumatologist and primary care management of cardiovascular disease risk in rheumatoid arthritis: patient and provider perspectives. Arthritis Care Res (Hoboken) 2016;68(4):415–423. doi: 10.1002/acr.22689.
    1. Schulz DN, Candel MJ, Kremers SP, Reinwand DA, Jander A, de Vries H. Effects of a Web-based tailored intervention to reduce alcohol consumption in adults: randomized controlled trial. J Med Internet Res. 2013;15(9):e206. doi: 10.2196/jmir.2568.
    1. Thiboutot J, Sciamanna CN, Falkner B, et al. Effects of a web-based patient activation intervention to overcome clinical inertia on blood pressure control: cluster randomized controlled trial. J Med Internet Res. 2013;15(9):e158. doi: 10.2196/jmir.2298.
    1. Tang TS, Funnell M, Sinco B, et al. Comparative effectiveness of peer leaders and community health workers in diabetes self-management support: results of a randomized controlled trial. Diabetes Care. 2014;37(6):1525–1534. doi: 10.2337/dc13-2161.
    1. Tang TS, Funnell MM, Gillard M, Nwankwo R, Heisler M. Training peers to provide ongoing diabetes self-management support (DSMS): results from a pilot study. Patient Educ Couns. 2011;85(2):160–168. doi: 10.1016/j.pec.2010.12.013.
    1. Tang TS, Funnell MM, Gillard M, Nwankwo R, Heisler M. The development of a pilot training program for peer leaders in diabetes: process and content. Diabetes Educ. 2011;37(1):67–77. doi: 10.1177/0145721710387308.
    1. Thom DH, Ghorob A, Hessler D, De Vore D, Chen E, Bodenheimer TA. Impact of peer health coaching on glycemic control in low-income patients with diabetes: a randomized controlled trial. Ann Fam Med. 2013;11(2):137–144. doi: 10.1370/afm.1443.
    1. Horvath KJ, Oakes JM, Rosser BR, et al. Feasibility, acceptability and preliminary efficacy of an online peer-to-peer social support ART adherence intervention. AIDS Behav. 2013;17(6):2031–2044. doi: 10.1007/s10461-013-0469-1.
    1. Shah S, Peat JK, Mazurski EJ, et al. Effect of peer led programme for asthma education in adolescents: cluster randomised controlled trial. Bmj. 2001;322(7286):583–585. doi: 10.1136/bmj.322.7286.583.
    1. Fisher EB, Jr, Strunk RC, Sussman LK, et al. Acceptability and feasibility of a community approach to asthma management: the Neighborhood Asthma Coalition (NAC) J Asthma. 1996;33(6):367–383. doi: 10.3109/02770909609068182.
    1. Young SD, Zhao M, Teiu K, Kwok J, Gill H, Gill N. A social-media based HIV prevention intervention using peer leaders. J Consumer Health Internet. 2013;17(4):353–361. doi: 10.1080/15398285.2013.833445.
    1. Turner BJ, Hollenbeak CS, Liang Y, Pandit K, Joseph S, Weiner MG. A randomized trial of peer coach and office staff support to reduce coronary heart disease risk in African-Americans with uncontrolled hypertension. J Gen Intern Med. 2012;27(10):1258–1264. doi: 10.1007/s11606-012-2095-4.
    1. Shadick NA, Zibit MJ, Iannaccone CK, et al. A development and feasibility study of a peer support telephone program in rheumatoid arthritis. J Clin Rheumatol: Pract Rep Rheumatic Musculoskelet Dis. 2018;24(6):346–349. doi: 10.1097/RHU.0000000000000661.
    1. Glasgow RE, Vogt TM, Boles SM. Evaluating the public health impact of health promotion interventions: the RE-AIM framework. Am J Public Health. 1999;89(9):1322–1327. doi: 10.2105/AJPH.89.9.1322.
    1. Bandura A. Social cognitive theory: an agentic perspective. Annu Rev Psychol. 2001;52:1–26. doi: 10.1146/annurev.psych.52.1.1.
    1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285–e350. doi: 10.1016/j.jacc.2018.11.003.
    1. Knowles M. The adult learner: a neglected species. Houston: Gulf Publishing; 1984.
    1. Carmel AS, Cornelius-Schecter A, Frankel B, et al. Patient education and counseling. 2019. Evaluation of the Patient Activated Learning System (PALS) to improve knowledge acquisition, retention, and medication decision making among hypertensive adults: Results of a pilot randomized controlled trial.
    1. Nowell WB, Curtis JR, Crow-Hercher R. Patient governance in a patient-powered research network for adult rheumatologic conditions. Med Care. 2018;56(Suppl 10 Suppl 1):S16–s21. doi: 10.1097/MLR.0000000000000814.
    1. Andreae SJ, Andreae LJ, Cherrington AL, et al. Development of a community health worker-delivered cognitive behavioral training intervention for individuals with diabetes and chronic pain. Fam Community Health. 2018;41(3):178–184. doi: 10.1097/FCH.0000000000000197.
    1. Miller WR. Motivational interviewing: research, practice, and puzzles. Addict Behav. 1996;21(6):835–842. doi: 10.1016/0306-4603(96)00044-5.
    1. Pincus T, Swearingen CJ, Bergman M, Yazici Y. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. J Rheumatol. 2008;35(11):2136–2147. doi: 10.3899/jrheum.080182.
    1. Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705–714. doi: 10.1016/0277-9536(91)90150-B.
    1. Hibbard JH, Stockard J, Mahoney ER, Tusler M. Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004;39(4 Pt 1):1005–1026. doi: 10.1111/j.1475-6773.2004.00269.x.
    1. Kroenke K, Strine TW, Spitzer RL, Williams JB, Berry JT, Mokdad AH. The PHQ-8 as a measure of current depression in the general population. J Affect Disord. 2009;114(1-3):163–173. doi: 10.1016/j.jad.2008.06.026.
    1. Cameron KA, Ross EL, Clayman ML, et al. Measuring patients’ self-efficacy in understanding and using prescription medication. Patient Educ Couns. 2010;80(3):372–376. doi: 10.1016/j.pec.2010.06.029.
    1. Dur M, Coenen M, Stoffer MA, et al. Do patient-reported outcome measures cover personal factors important to people with rheumatoid arthritis? A mixed methods design using the International Classification of Functioning, Disability and Health as frame of reference. Health Qual Life Outcomes. 2015;13:27. doi: 10.1186/s12955-015-0214-8.
    1. Pincus T, Yazici Y, Bergman MJ. RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. Rheum Dis Clin North Am. 2009;35(4):773–778, viii. doi: 10.1016/j.rdc.2009.10.008.
    1. Schwarzer R, Jerusalem, M. Generalized Self-Efficacy scale. In: J. Weinman SW, & M. Johnston, ed. Measures in health psychology: A user’s portfolio. Causal and control beliefs. Windsor: NFER-NELSON; 1995:35-37.
    1. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford) 2013;52(1):53–61. doi: 10.1093/rheumatology/kes305.
    1. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. Arthritis Rheum. 2000;43(3):522–530. doi: 10.1002/1529-0131(200003)43:3<522::AID-ANR7>;2-Y.
    1. Coulson KA, Reed G, Gilliam BE, Kremer JM, Pepmueller PH. Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry. J Clin Rheumatol: Pract Rep Rheumatic Musculoskelet Dis. 2009;15(4):155–160. doi: 10.1097/RHU.0b013e3181a5679d.
    1. Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17(1):212. doi: 10.1186/s13075-015-0728-9.
    1. Navarro-Millán I, Cornelius-Schecter A, O'Beirne RJ, et al. Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis. BMC Rheumatol. 2020;4:14. doi: 10.1186/s41927-020-0112-5.
    1. Forsythe LP, Carman KL, Szydlowski V, et al. Patient engagement in research: early findings from the Patient-Centered Outcomes Research Institute. Health Aff. 2019;38(3):359–367. doi: 10.1377/hlthaff.2018.05067.
    1. Richards DP, Birnie KA, Eubanks K, et al. Guidance on authorship with and acknowledgement of patient partners in patient-oriented research. Res Involv Engagem. 2020;6:38. doi: 10.1186/s40900-020-00213-6.
    1. Staniszewska S, Brett J, Mockford C, Barber R. The GRIPP checklist: strengthening the quality of patient and public involvement reporting in research. Int J Technol Assess Health Care. 2011;27(4):391–399. doi: 10.1017/S0266462311000481.
    1. Nowell WB, Merkel PA, McBurney RN, et al. Patient-powered research networks of the autoimmune research collaborative: rationale, capacity, and future directions. 2021;14(6):699–710.
    1. ASCVD Risk Estimator Plus. American College of Cardiology. Accessed 1 Sept 2021.
    1. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377–399. doi: 10.1002/sim.4067.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren